Roswell Park Comprehensive Cancer Center Discovers CX3CR1 to Predict Patient Benefit from Checkpoint Inhibitors

Jun 25, 2020 | anti-PD-1 therapy, Biomarker, Checkpoint Inhibitors, News, Oncology

Roswell Park Comprehensive Cancer Center Discovers CX3CR1 to Predict Patient Benefit from Checkpoint Inhibitors

Roswell Park Comprehensive Cancer Center’s Fumito Ito, MD, PhD, FACS highlighted new evidence of a powerful predictive biomarker that can help researchers distinguish between non-small cell lung cancer (NSCLC) cancer patients as to who can benefit from checkpoint inhibitors and who will not. This capability would transform oncology care as it infuses far more granular precision into directing what can be expensive treatments with considerable side effects. What if such a predictive ability did exist via a blood test involving the measurement of the levels of the chemokine receptor CX3CR1 in patients’ immune cells: specifically their T lymphocytes?

Roswell Presents the Predictive Biomarkers at AAR Virtual Meeting

Dr. Fumito Ito from Roswell Park Comprehensive Cancer Center (Roswell) will present to the American Association for Cancer Research (AAR) Virtual Meeting II this new evidence providing that the Buffalo New York-based research center has made an incredibly valuable stride. After all, they have wrapped up a clinical trial assessing this actual predictive biomarker: one that can predict response to therapies that target checkpoint protein PD-1: the checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda).

CX3CR1: The Biomarker

This Roswell-discovered biomarker is called CX3CR1, and at the forthcoming event Dr. Ito will outline just how accurate it is for NSCLC patients currently under treatment with anti-PD-1 therapy. What would be the value of this new predictive biomarker? How important would it be to minimize unnecessary treatment and associated treatment toxicity and cost? What if this predictive biomarker could be applied not only to patients with NSCLC but also those with other forms of cancers?


This biomarker research project has been funded internally by Roswell Park and from a grant from the U.S. Department of Defense

About Roswell Park

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Funded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York.

Lead Research/Investigator

Dr. Fumito Ito from Roswell Park Comprehensive Cancer Center, Associate Professor of Surgical Oncology, member of Center for Immunotherapy at Roswell Park

Call to Action: Check out Dr. Ito’s presentation of the study via Abstract 1044 that occurred yesterday, June 24, 2020.

Source: Roswell Park


Pin It on Pinterest